These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 15257231)
1. [Cardiovascular effects of rosiglitazone]. Le Feuvre C Presse Med; 2004 Jun; 33(11):735-45. PubMed ID: 15257231 [TBL] [Abstract][Full Text] [Related]
2. [Heart, diabetes and glitazones]. Le Feuvre C Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S26-35. PubMed ID: 15163921 [TBL] [Abstract][Full Text] [Related]
3. [Heart failure with thiazolidinedione treatment: what do we know today?]. Erdmann E Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858 [TBL] [Abstract][Full Text] [Related]
4. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Simó R; Rodriguez A; Caveda E Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732 [TBL] [Abstract][Full Text] [Related]
5. [Glucose-independent impact of the glitazones on the cardiovascular outcome]. Hanefeld M MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569 [TBL] [Abstract][Full Text] [Related]
6. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Sarafidis PA Fundam Clin Pharmacol; 2008 Jun; 22(3):247-64. PubMed ID: 18422634 [TBL] [Abstract][Full Text] [Related]
7. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Defronzo RA; Mehta RJ; Schnure JJ Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744 [TBL] [Abstract][Full Text] [Related]
8. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Stafylas PC; Sarafidis PA; Lasaridis AN Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530 [TBL] [Abstract][Full Text] [Related]
9. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials]. De Flines J; Scheen AJ Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661 [TBL] [Abstract][Full Text] [Related]
10. [Rosiglitazone: no increase in cardiovascular mortality]. Jazet IM; Meinders AE Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745 [TBL] [Abstract][Full Text] [Related]
11. [Rosiglitazone: a clinical development focused on cardio-vascular prevention]. Valensi P Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506 [TBL] [Abstract][Full Text] [Related]
12. The cardiovascular safety of rosiglitazone. Ajjan RA; Grant PJ Expert Opin Drug Saf; 2008 Jul; 7(4):367-76. PubMed ID: 18613801 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk and cardiometabolic protection: role of glitazones. Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866 [TBL] [Abstract][Full Text] [Related]
14. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323 [TBL] [Abstract][Full Text] [Related]
17. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Singh S; Loke YK; Furberg CD JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Dahabreh IJ; Economopoulos K Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649 [TBL] [Abstract][Full Text] [Related]
19. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894 [TBL] [Abstract][Full Text] [Related]
20. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?]. Haberbosch W Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]